Fabrazyme®

Understanding Fabrazyme® 

Fabrazyme® (agalsidase beta) is an enzyme replacement therapy (ERT) used to treat Fabry disease, a rare genetic disorder caused by a deficiency of the enzyme α-galactosidase A. This deficiency leads to the accumulation of globotriaosylceramide (GL-3) in various organs, including the kidneys, heart, and nervous system, resulting in progressive damage. Fabrazyme® helps slow disease progression by reducing GL-3 buildup, preserving kidney and heart function, and improving quality of life for Fabry disease patients. As a lifelong treatment, Fabrazyme® is most effective when started early to prevent irreversible organ damage.

How Fabrazyme® Works:

• Replaces the missing α-galactosidase A enzyme, helping break down GL-3.
• Reduces the accumulation of harmful substances in key organs.
• Slows disease progression and preserves organ function.

FDA Approval:

• Fabrazyme® (agalsidase beta): Approved in 2003.

For more information, please visit the Fabrazyme® patient website and speak with your healthcare provider to determine if Fabrazyme® is the right treatment option for you.